Clinical Trial Update: Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating osimertinib with or without bevacizumab for EGFR-mutant non-small cell lung cancer with leptomeningeal metastasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Osimertinib (osimertinib)

Snippet

Sponsor: Second Affiliated Hospital of Nanchang University | Conditions: Leptomeningeal Metastasis, Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN